127 related articles for article (PubMed ID: 2283479)
1. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V
Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479
[TBL] [Abstract][Full Text] [Related]
2. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
3. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
[TBL] [Abstract][Full Text] [Related]
5. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR
Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480
[TBL] [Abstract][Full Text] [Related]
6. A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients.
Nicolini A; Carpi A; Di Marco G; Giuliani L; Giordani R; Palla S
Cancer; 1989 May; 63(10):2037-46. PubMed ID: 2702573
[TBL] [Abstract][Full Text] [Related]
7. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR
Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513
[TBL] [Abstract][Full Text] [Related]
8. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
9. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.
Stieber P; Nagel D; Ritzke C; Rössler N; Kirsch CM; Eiermann W; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):809-14. PubMed ID: 1489855
[TBL] [Abstract][Full Text] [Related]
10. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
12. Serum osteocalcin concentration in patients with prostatic cancer.
Francini G; Bigazzi S; Leone V; Gennari C
Am J Clin Oncol; 1988; 11 Suppl 2():S83-7. PubMed ID: 3266542
[TBL] [Abstract][Full Text] [Related]
13. A profile of serum CA 15-3, carcinoembryonic antigen, alkaline phosphatase, and gamma-glutamyl transferase levels in patients with breast cancer.
Buamah PK; Bent DJ; Bodger WA; Skillen AW
J Surg Oncol; 1993 Jun; 53(2):84-7. PubMed ID: 8099132
[TBL] [Abstract][Full Text] [Related]
14. Biochemical markers for assessment of bone metastases in patients with breast cancer.
Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ
Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
[TBL] [Abstract][Full Text] [Related]
15. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
[TBL] [Abstract][Full Text] [Related]
16. [Whole-body retention of 99mTc-methylene diphosphonate in skeletal diseases].
Zorn-Bopp E; Büll U; Münzing W; Lang P; Moser EA
Nuklearmedizin; 1983 Feb; 22(1):24-30. PubMed ID: 6223277
[TBL] [Abstract][Full Text] [Related]
17. The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
Makaiová I; Kausitz J; Hupka S; Michaliková B; Vivodová M; Bohunický L
Czech Med; 1989; 12(1):34-9. PubMed ID: 2498049
[TBL] [Abstract][Full Text] [Related]
18. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
Nicolini A; Ferrari P; Sagripanti A; Carpi A
Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
20. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]